GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncotelic Therapeutics Inc (OTCPK:OTLC) » Definitions » Long-Term Debt & Capital Lease Obligation

Oncotelic Therapeutics (Oncotelic Therapeutics) Long-Term Debt & Capital Lease Obligation : $1.90 Mil (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Oncotelic Therapeutics Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Oncotelic Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.90 Mil.

Warning Sign:

Oncotelic Therapeutics Inc keeps issuing new debt. Over the past 3 years, it issued USD 4.942 million of debt.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Oncotelic Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.90 Mil. Oncotelic Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $30.02 Mil. Oncotelic Therapeutics's LT-Debt-to-Total-Asset for the quarter that ended in Dec. 2023 was 0.06.

Oncotelic Therapeutics's LT-Debt-to-Total-Asset increased from Dec. 2022 (0.00) to Dec. 2023 (0.06). It may suggest that Oncotelic Therapeutics is progressively becoming more dependent on debt to grow their business.


Oncotelic Therapeutics Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Oncotelic Therapeutics's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncotelic Therapeutics Long-Term Debt & Capital Lease Obligation Chart

Oncotelic Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.90

Oncotelic Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.90 1.90

Oncotelic Therapeutics Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Oncotelic Therapeutics  (OTCPK:OTLC) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Oncotelic Therapeutics's LT-Debt-to-Total-Asset ratio for the quarter that ended in Dec. 2023 is calculated as:

LT-Debt-to-Total-Asset (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=1.898/30.015
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Oncotelic Therapeutics Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Oncotelic Therapeutics's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Executives
Vuong Trieu officer: CHIEF EXECUTIVE OFFICER 4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301
Saran Saund officer: CHIEF BUSINESS OFFICER C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301
Amit B. Shah officer: CHIEF FINANCIAL OFFICER 10 AGUILA, ALISO VIEJO CA 92656
Chulho Park officer: CHIEF TECHNOLOGY OFFICER 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Maida Anthony E Iii director 157 TECHNOLOGY DR, IRVINE CA 92618
Steven W King director
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Fatih Uckun 10 percent owner, officer: Chief Medical Officer 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Chao Hsiao 10 percent owner 701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Larn Hwang 10 percent owner C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Donald Rogers Reynolds director C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607
Sandage Bobby W Phd director C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173
Simon Pedder director 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Matthew M Loar officer: Chief Financial Officer 505 PENOBSCOT DR, REDWOOD CITY CA 94063
Pamela Ha officer: Controller 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080

Oncotelic Therapeutics (Oncotelic Therapeutics) Headlines